Henry Schein, Inc. (NASDAQ:HSIC) to Post Q2 2024 Earnings of $1.27 Per Share, Zacks Research Forecasts

Henry Schein, Inc. (NASDAQ:HSIC) – Research analysts at Zacks Research raised their Q2 2024 earnings per share estimates for Henry Schein in a note issued to investors on Wednesday, May 1st. Zacks Research analyst U. Biswas now expects that the company will earn $1.27 per share for the quarter, up from their previous estimate of $1.26. The consensus estimate for Henry Schein’s current full-year earnings is $5.07 per share. Zacks Research also issued estimates for Henry Schein’s Q1 2025 earnings at $1.34 EPS.

Henry Schein (NASDAQ:HSIC) last posted its earnings results on Tuesday, May 7th. The company reported $1.10 earnings per share for the quarter, beating the consensus estimate of $1.01 by $0.09. The company had revenue of $3.17 billion for the quarter, compared to analyst estimates of $3.21 billion. Henry Schein had a return on equity of 14.03% and a net margin of 3.37%. Henry Schein’s revenue was up 3.7% compared to the same quarter last year. During the same quarter in the prior year, the company earned $1.21 earnings per share.

A number of other research firms have also issued reports on HSIC. Piper Sandler upped their target price on shares of Henry Schein from $78.00 to $86.00 and gave the company an “overweight” rating in a report on Monday, February 26th. TheStreet raised shares of Henry Schein from a “c+” rating to a “b-” rating in a research note on Monday, February 26th. Barrington Research upped their price objective on shares of Henry Schein from $82.00 to $90.00 and gave the company an “outperform” rating in a research note on Wednesday, February 28th. Jefferies Financial Group upped their price objective on shares of Henry Schein from $74.00 to $81.00 and gave the company a “hold” rating in a research note on Wednesday, March 6th. Finally, Evercore ISI upped their price objective on shares of Henry Schein from $79.00 to $83.00 and gave the company an “in-line” rating in a research note on Wednesday, February 28th. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating and five have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $81.09.

Henry Schein Stock Up 3.9 %

Henry Schein stock opened at $71.20 on Monday. The company has a debt-to-equity ratio of 0.45, a quick ratio of 1.00 and a current ratio of 1.67. The firm has a market capitalization of $9.15 billion, a price-to-earnings ratio of 22.60, a price-to-earnings-growth ratio of 1.68 and a beta of 0.87. Henry Schein has a fifty-two week low of $60.01 and a fifty-two week high of $82.63. The stock’s fifty day moving average is $73.08 and its two-hundred day moving average is $72.34.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the stock. Boston Partners lifted its position in shares of Henry Schein by 144.1% in the 4th quarter. Boston Partners now owns 2,637,429 shares of the company’s stock worth $199,393,000 after buying an additional 1,556,831 shares during the last quarter. Norges Bank bought a new position in shares of Henry Schein in the 4th quarter worth about $111,715,000. Nuance Investments LLC bought a new position in shares of Henry Schein in the 4th quarter worth about $103,446,000. Lazard Asset Management LLC lifted its position in shares of Henry Schein by 1,303.3% in the 3rd quarter. Lazard Asset Management LLC now owns 1,247,334 shares of the company’s stock worth $92,614,000 after buying an additional 1,158,451 shares during the last quarter. Finally, Fiduciary Management Inc. WI lifted its position in shares of Henry Schein by 17.1% in the 4th quarter. Fiduciary Management Inc. WI now owns 2,284,337 shares of the company’s stock worth $172,947,000 after buying an additional 333,855 shares during the last quarter. 96.62% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Henry Schein

In other news, CEO Bradford C. Connett sold 6,430 shares of the stock in a transaction on Wednesday, March 20th. The shares were sold at an average price of $74.28, for a total value of $477,620.40. Following the completion of the sale, the chief executive officer now owns 73,108 shares of the company’s stock, valued at $5,430,462.24. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. In related news, CEO Bradford C. Connett sold 6,430 shares of the firm’s stock in a transaction on Wednesday, March 20th. The shares were sold at an average price of $74.28, for a total transaction of $477,620.40. Following the completion of the sale, the chief executive officer now directly owns 73,108 shares of the company’s stock, valued at approximately $5,430,462.24. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Vice Chairman James P. Breslawski sold 2,907 shares of the firm’s stock in a transaction on Monday, March 18th. The shares were sold at an average price of $74.37, for a total transaction of $216,193.59. Following the sale, the insider now directly owns 209,562 shares of the company’s stock, valued at $15,585,125.94. The disclosure for this sale can be found here. Company insiders own 1.14% of the company’s stock.

About Henry Schein

Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.